LPU Labor für Pharma- und Umweltanalytik GmbH provides chemical-pharmaceutical analyses, process development and the handling and support of pharmaceutical, cosmetic and dietary products. The company operates service laboratories in Graefelfing and Planegg‑Martinsried; the Graefelfing location additionally offers consulting services including the preparation and processing of regulatory filings for European authorities. LPU was acquired by the GBA laboratory group in August 2014 and merged with LAT GmbH Dr. Tittel, Institute for Pharma Analytics in January 2015. In the 2015 fiscal year the company employed on average 92 staff and emphasizes a strong quality orientation and personal customer service.
Durchführung chemisch-pharmazeutischer Analysen, verfahrenstechnische Entwicklung, Bearbeitung und Betreuung von pharmazeutischen, kosmetischen und diätischen Produkten, deren behördliche Zulassung und Vertrieb.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) München Local Court, HRB 194517 (as of 1 November 2026)
| Name | Type | City |
|---|---|---|
| Birgit Schumacher | Geschäftsführer(in) | Pfaffenhofen |
Source: German Commercial Register (Handelsregister) München Local Court, HRB 194517 (as of 1 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2015 | Rohergebnis€7M2 | €471,356 | €4,796,059 | — |
| 2014 | Rohergebnis€4.8M2 | €324,533 | €7,284,253 | — |
| 2013 | Rohergebnis€3.4M2 | €66,157 | €2,338,588 | — |
| 2012 | small company1 | €251,662 | €2,190,792 | — |
| 2011 | small company1 | €498,783 | €2,070,600 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) München Local Court, HRB 194517 (as of 1 November 2026)
Bionic Medizintechnik GmbH
Friedrichsdorf · Herstellung von pharmazeutischen Grundstoffen
Medios Solutions Stuttgart GmbH
Magstadt · Herstellung von pharmazeutischen Grundstoffen
BODY PRODUCTS RELAX Pharma und Kosmetik GmbH
Frechen · Herstellung von medizinischen und zahnmedizinischen Apparaten und Materialien a. n. g.
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €4,274,708 | 92.5% |
| Depreciation | €336,497 | 7.3% |
| Interest & Similar | €7,780 | 0.2% |
